

香港聯合交易所有限公司

(香港交易及結算所有限公司全資附屬公司)

THE STOCK EXCHANGE OF HONG KONG LIMITED

(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

通告 CIRCULAR

香港聯合交易所有限公司竭力確保其提供之資料準確可靠，惟不保證該等資料絕對正確，亦不對由於任何資料不確或遺漏所引之損失或損害負上責任(不論是民事侵權行為責任或合約責任或其他)。

The Stock Exchange of Hong Kong Limited endeavours to ensure the accuracy and reliability of the information provided, but does not guarantee its accuracy and accepts no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions

FOR REFERENCE ONLY

Subject : Display of Previous Closing Price of Lee's Pharmaceutical Holdings Limited (stock Code 950) on OTP-C for the Preferential Offering of 1 Reserved Share of Zhaoke Ophthalmology Limited for every 115 shares on Ex-All Date, 7 April 2021

Enquiry Tel : Mr. Leo Cheung (Tel: 2840 3450) or Ms. Grace Leung (Tel: 2840 3797)

Lee's Pharmaceutical Holdings Limited ("Lee's Pharmaceutical") announced a spin-off proposal for a separate listing of Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology") (the "Proposed Spin-Off"). Qualifying shareholders of Lee's Pharmaceutical will be entitled to apply for 1 Reserved Share of Zhaoke Ophthalmology for every 115 shares (the "Preferential Offering"). According to the timetable for the Preferential Offering, Lee's Pharmaceutical's shares (stock code: 950) will be marked "ex-all" on 7 April 2021, the Ex-All Date.

Given that the exact value of the Reserved Shares of Zhaoke Ophthalmology is not known, the Exchange will display "N/A" in the "PRV CLOSE" field of Lee's Pharmaceutical's OTP-C stock page on 7 April 2021, the Ex-All Date in accordance with the OTP-C standard practice. The unadjusted previous closing price will be displayed in the free text field.

Shareholders, investors and market participants should read the announcement issued by Lee's Pharmaceutical in full including the terms and conditions of the Proposed Spin-Off and the Preferential Offering in dealing with Lee's Pharmaceutical's shares. If they are in doubt, they should consult their professional adviser(s).

Charles Woo
Vice President
Listing Division